Scarna9: A Protein Target for Neurological and Cardiovascular Diseases

Target Name: SCARNA9

NCBI ID: G619383

SCARNA9

Other Name(s): mgU2-19/30 | small Cajal body-specific RNA 9 | Small Cajal body-specific RNA 9 | MgU2-19/30 | Z32

Scarna9: A Protein Target for Neurological and Cardiovascular Diseases

SCARNA9 (mgU2-19/30) is a protein that is expressed in various tissues of the body, including the nervous system, endothelial cells, and epithelial cells. It is a member of the G-protein-coupled receptor (GPCR) family and is involved in the regulation of cellular signaling pathways that are critical for various physiological processes, including cell survival, growth, and differentiation.

Recent studies have identified SCARNA9 as a potential drug target for various neurological and cardiovascular diseases, due to its involvement in multiple signaling pathways that are implicated in these conditions. For example, SCARNA9 has been shown to be involved in the regulation of neurogenesis, which is the process by which new neurons are generated in the brain, and has been linked to the development of various neurological disorders, such as Alzheimer's disease and Parkinson's disease.

Additionally, SCARNA9 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body, and has been linked to the development of various cardiovascular diseases, such as heart failure and hypertension.

In addition to its involvement in neurogenesis and angiogenesis, SCARNA9 has also been shown to play a role in the regulation of cellular signaling pathways that are critical for cell survival and growth. For example, it has been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together and form tissues, and has been linked to the development of various diseases, such as cancer.

Furthermore, SCARNA9 has also been shown to play a role in the regulation of inflammation, which is a critical immune response that helps the body fight off infections and diseases.

In conclusion, SCARNA9 is a protein that is involved in multiple signaling pathways that are critical for various physiological processes in the body. Its potential as a drug target makes it an attractive target for the development of new treatments for a variety of neurological and cardiovascular diseases. Further research is needed to fully understand the role of SCARNA9 in cellular signaling pathways and its potential as a drug target.

Protein Name: Small Cajal Body-specific RNA 9

The "SCARNA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets